Discovery of a non-peptidic inhibitor of West Nile virus NS3 protease by high-throughput docking by Ekonomiuk, Dariusz et al.
Discovery of a Non-Peptidic Inhibitor of West Nile Virus
NS3 Protease by High-Throughput Docking
Dariusz Ekonomiuk1, Xun-Cheng Su2, Kiyoshi Ozawa2, Christophe Bodenreider3, Siew Pheng Lim3,
Zheng Yin3, Thomas H. Keller3, David Beer3, Viral Patel3, Gottfried Otting2, Amedeo Caflisch1, Danzhi
Huang1*
1Department of Biochemistry, University of Zu¨rich, Zu¨rich, Switzerland, 2 Research School of Chemistry, The Australian National University, Canberra, Australia, 3Novartis
Institute for Tropical Diseases, Chromos, Singapore
Abstract
Background: The non-structural 3 protease (NS3pro) is an essential flaviviral enzyme and therefore one of the most
promising targets for drug development against West Nile virus (WNV) and dengue infections.
Methodology: In this work, a small-molecule inhibitor of the WNV NS3pro has been identified by automatic fragment-based
docking of about 12000 compounds and testing by nuclear magnetic resonance (NMR) spectroscopy of only 22 molecules.
Specific binding of the inhibitor into the active site of NS3pro and its binding mode are confirmed by 15N-HSQC NMR
spectra. The inhibitory activity is further validated by an enzymatic assay and a tryptophan fluorescence quenching assay.
Conclusion: The inhibitor [4-(carbamimidoylsulfanylmethyl)-2,5-dimethylphenyl]-methylsulfanylmethanimidamide has a
good ratio of binding affinity versus molecular weight (ligand efficiency of 0.33 kcal/mol per non-hydrogen atom), and thus
has good potential as lead compound for further development to combat West Nile virus infections.
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Introduction
West Nile virus (WNV) and the closely related dengue virus,
members of the family Flaviviridae, are worldwide-spread global
threats transmitted by mosquito bites. WNV encephalitis infects
mainly birds but also other vertebrates including humans. It has
been reported in four continents during the last decade [1] and has
been spreading in North America causing several thousand cases
per year since 1999 [2]. Despite its growing distribution and
epidemic character, there are no specific antiviral treatments that
can prevent or cure this infection.
The non-structural 3 protease (NS3pro) is one of the most
promising targets for drug development against flaviviridae
infections because it is responsible for cleavage of the viral
polyprotein precursor and plays a pivotal role in viral replication
[3,4]. Moreover, two inhibitors of the closely related hepatitis C
virus protease are under late-stage development [5,6,7,8]. Site
directed mutagenesis focused on the NS3pro cleavage sites in the
polyprotein precursor abolishes viral infectivity [4]. Furthermore,
the activity of NS3pro is significantly increased by the presence of
a 47-residue region of the non-structural cofactor 2B (NS2B) [9].
There are two X-ray structures of WNV NS2B-NS3pro (the term
‘protease’ will be used in the following to simplify notation) in
complex with inhibitors: one with the substrate-based tetrapeptide
benzoyl-norleucine-lysine-arginine-arginine-aldehyde (Bz-Nle-Lys-
Arg-Arg-H, PDB code 2fp7 [10]) and the other with bovine
pancreatic trypsin inhibitor (BPTI, PDB code 2ijo [11]). The two
X-ray structures with different inhibitors have similar conforma-
tions of the protease and are therefore appropriate for structure-
based drug design. (Note that only the complex with the
tetrapeptide inhibitor was available when the fragment-based
docking was performed). The protease adopts a chymotrypsin-like
fold with two six-stranded b-barrels. The binding pocket is small
and very shallow with the catalytic triad (His51-Asp75-Ser135)
located at the cleft between the two b-barrels.
The WNV protease is a very difficult target as is witnessed by the
very small number of known non-peptidic inhibitors. Furthermore,
only few molecules emerged as inhibitors of the WNV protease (in
the micromolar range) from a library of more than one million
compounds submitted to a high-throughput in vitro screening
campaign [12]. Recently published efforts on inhibitor development
against flaviviral proteases focused mostly on peptidomimetics
[13,14,15,16] and only few non-peptidic compounds have been
reported [17,18,19] leaving open space for further investigation
aimed at viral chemotherapy. The preferred amino acids at the
nonprime part of the protease active site are arginine at the P1
position and arginine or lysine at the P2 position [4] underlining the
role of electrostatic interactions with the negatively charged S1 and
S2 pockets. Most of the reported active compounds have charged
moieties, with the guanidino group being the most frequent. They
include a class of D-arginine based 9–12 mer peptides [14], peptide
aldehyde inhibitors [13,16], and five non-peptidic guanidino
compounds reported by Ganesh et al. [17]. Non-charged inhibitors
include a series of 8-hydroxyquinoline [19], some uncompetitive
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inhibitors [18], and 15 inhibitors reported in PubChem BioAssay
database [20]. Inhibitors for the close related NS3 proteases of
Hepatitis C, dengue, and yellow fever virus have also been identified
[8,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]. In this paper, we
report the discovery of a WNV protease inhibitor by our in silico
high-throughput screening approach and experimental validations.
Methods
The in silico screening was performed by a fragment-based
docking procedure and an efficient evaluation of binding free energy
with electrostatic solvation. All of the calculations were performed
on the WNV protease from its complex with the tetrapeptide
inhibitor Bz-Nle-Lys-Arg-Arg-H (PDB code 2fp7 [10]).
Evaluation of Binding Free Energy with LIECE
The linear interaction energy with continuum electrostatics
(LIECE) approach was introduced and tested first on aspartic
proteases [36] and recently further validated on kinases [37].
Here, only a brief overview of the method is presented, while the
development of the LIECE model for the WNV protease is
presented in the section Results and Discussion. The essential idea
of linear interaction energy models is that the free energy of
binding can be calculated by considering only the end points of the
thermodynamic cycle of ligand binding, i.e., bound and free states.
For this purpose, one usually calculates average values of
interaction energies from molecular dynamics (MD) simulations
of the isolated ligand and the ligand/protein complex [38,39]. In
this way, the free energy of binding can be approximated by
DGbind~
1
2
SEelecTbound{SE
elecTfree
 
za SEvdWTbound{SE
vdWTfree
  ð1Þ
where Eelec and EvdW are the electrostatic and van der Waals
interaction energies between the ligand and its surroundings. The
surroundings are either the solvent (free) or the solvated protein
(bound ), and the Ææ denotes an ensemble average sampled usually
by explicit water MD simulations. We have suggested that it is
possible to avoid the MD sampling by replacing it with a simple
energy minimization, and postprocessing of the minimized
structures by a rigorous treatment of solvation within the
continuum electrostatics approximation [36]. The LIECE ap-
proach is very efficient and has a predictive accuracy of about
1.0 kcal/mol for 13 and 29 peptidic inhibitors of BACE-1 and
HIV-1 protease, respectively [36]. Similar accuracy has been
reported recently for five kinases [37].
Preparation of the Protease Structure
The coordinates of WNV protease in the complex with the
tetrapeptide aldehyde inhibitor Bz-Nle-Lys-Arg-Arg-H were
downloaded from the PDB database (PDB entry 2fp7 [10]). All
water molecules were removed. The spurious termini at the
segment missing in the X-ray structure (residues 28–32 in chain B)
were neutralized by the 2COCH3 group and the 2NHCH3
group at the N-terminus and C-terminus, respectively. The 37
peptidic inhibitors used in this study include Bz-Nle-Lys-Arg-Arg-
H (IC50 = 4.1 mM) and a series of 36 related inhibitors with an
aldehyde warhead and two or three positively charged side chains
(IC50 values ranging from 0.4 to 463 mM, see Text S1) synthesized
in the same laboratory and tested all with the same enzymatic
assay [13]. The initial binding conformations were modeled
manually according to the binding mode of Bz-Nle-Lys-Arg-Arg-
H because all inhibitors have similar backbone structure and are
covalently bound to the Ser135 side chain by an ester linkage.
For a covalently bound inhibitor, the binding energy can be
decomposed into DGbind~DGnoncovalentzDGcovalent. Noncovalent
interaction energies in covalent complexes had been investigated
before [40,41]. In the case of irreversible inhibitors, DGcovalent is
determinant, and therefore improving the noncovalent comple-
mentarity within a covalently bound complex does not necessarily
improve the potency of an inhibitor [40]. For reversible inhibitors,
e.g., the 37 peptidic inhibitors used in this study [13], DGnoncovalent
and DGcovalent are both important for binding. Since the peptidic
inhibitors have similar backbone structure and there is no large
conformational change of the protein upon minimization, we
assume that the energy contributions from DGcovalent is similar for
all inhibitors and the differences in binding affinities originate from
DGnoncovalent. Therefore, for interaction energy calculations, the
atoms involved in the ester bond between protein and inhibitor
were neglected as well as the adjacent -OH group of Ser135 and -
C(H)OH group of inhibitor to avoid steric clashes. The resulting
empty valencies on protein and inhibitors were filled with
hydrogen atoms.
Preparation of the Compound Libraries
The compounds were selected by applying strict filtering criteria
from the iResearch database (ChemNavigator Inc., 2006) using
Filter v2.0.1 (OpenEye Scientific Software, Inc.). The selection of
compounds was based on the property of the active site pockets S1
to S3, which contain 19 hydrogen bond acceptors. Therefore,
compounds with multiple hydrogen bond donors are expected to
have higher chances to bind. Furthermore, there are five aspartate
side chains in (or very close to) the S1–S3 pockets, and most of the
previously discovered peptidic and nonpeptidic inhibitors have at
least one positive charge [12,13]. Therefore, to generate a focussed
sublibrary, at least five hydrogen bond donors or one positive
charge was used as selection criteria. From a library of over 6
million molecules, only 11715 compounds met one of the two
criteria. Of these 11715 compounds, 5882 are neutral, 4198 have
one positive charge, 1503 have more than one positive charge, and
the remaining 132 compounds have negative charge(s). Final
preparation included the assignment of CHARMm atom types,
force field parameters [42], and partial charges [43,44], and
energy minimization with a distance dependent dielectric function
using the program CHARMM [45].
High-throughput Docking
The fragment-based docking of the database (of prefiltered
compounds) consists of four consecutive steps which have been
detailed in a previous work [46]. Briefly, the four steps are: (1)
Decomposition of each molecule of the library into mainly rigid
Author Summary
An estimated 2.5 billion people are at risk of diseases
caused by dengue and West Nile virus. As of today, there
are neither vaccines to prevent nor drugs to cure the
severe infections caused by these viruses. The NS3
protease is one of the most promising targets for drug
development against West Nile virus because it is an
essential enzyme for viral replication and because success
has been demonstrated with the closely related hepatitis C
virus protease. We have discovered a small molecule that
inhibits the NS3 protease of West Nile virus by computer-
aided high-throughput docking, and validated it using
three experimental techniques. The inhibitor has potential
to be developed to a drug candidate to combat West Nile
virus infections.
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fragments by the program DAIM [47], (2) fragment docking with
evaluation of electrostatic solvation [48,49] by the program SEED
[50,51], (3) flexible docking of each molecule of the library using
the position and orientation of its fragments as anchors by the
program FFLD [52,53], and (4) final minimization by CHARMM
[45] using the CHARMm force field [42] followed by evaluation
of the LIECE binding free energy for the best poses. The protein
structure was kept rigid in all steps. Furthermore, in all continuum
electrostatic calculations (in SEED and LIECE) the interior
dielectric constant was set to 2.0 to partially account for the
electronic polarizability and dipolar reorientation effects of the
solute [54]. The advantage of the multi-step approach used in this
and previous in silico high-throughput screening campaigns
[37,46,55] is that intermediate results (e.g., binding modes of
most favorable fragments) can be used to focus the screening [56].
Computational Requirements
The in silico screening of the nearly 12000 compounds, i.e.,
docking and binding energy evaluation, took about 30 hours on a
Beowulf cluster of 100 Opteron 1.8 GHz CPUs. The LIECE
approach requires 4 minutes (mainly for the finite-difference
Poisson calculations with grid spacing of 0.4 A˚) of a single Opteron
1.8 GHz CPU for each pose.
Enzymatic assay
The enzymatic assay was performed as described in Knox et al.
[13]. Briefly, compounds were mixed with 50 nM West Nile
CF40-gly-NS3pro187 and incubated at 37uC for 30 min in
50 mM Tris, pH 8.5 and 20% glycerol, followed by addition of
20 mM substrate, Bz-nKRR-AMC. The fluorophore, 7-amino-4-
methylcoumarin (AMC) group at the C-terminus becomes
fluorescent when cleaved from the peptide substrate. Reaction
progress was monitored continuously at 37uC (excitation 385 nm,
emission 465 nm) in a Victor3V plate reader (Perkin Elmer) as an
increase in fluorescence (RFU/min) which was then converted to
Ms21 from a standard AMC calibration curve. Percentage of
inhibition of enzyme activity was determined by comparing the
initial velocities in the enzyme reaction in presence of increasing
concentration of compound 1 (from 0 to 500 mM) against control
wells without compounds. IC50 values were derived for inhibitors
by fitting the calculated initial velocities to a non linear regression
curve using GraphPad Prism software. Each point of the IC50
curve was carried out in duplicate during a single experiment.
Tryptophan fluorescence assay
Binding of compound 1 was measured by a competition assay
with an noncovalently bound inhibitor (Kd~13 mM, see Text S1)
that quenched tryptophan fluorescence upon binding in the
protease active site [12]. 3 mM of protein were titrated by this
competitive inhibitor (from 0 to 40 mM) in the absence or presence
of varying concentrations of compound 1 (70, 140 and 210 mM) in
Tris 50 mM, pH 7.5, and NaCl 50 mM. 90 ml of each dilution
were thereafter transferred to a UV-star Greiner 96-wells
microplate. After 1 h incubation at room temperature, fluores-
cence was measured at 25uC on a Tecan Safire2 with
lexc~280 nm (bandwidth 10 nm) and lem~340 nm (bandwidth
20 nm). Kd for compound 1 was inferred from the effect of the
varying concentrations on the Kd of the reference compound as
described [57].
NMR Validation
NMR spectroscopy analysis (1H chemical shifts and 15N-HSQC
spectra) was performed as described elsewhere [58]. The Lys96 to
Ala single-point mutant of the NS2B cofactor (NS2B(K96A)) was
used because it significantly reduced self-cleavage, preventing
gradual build-up of sample heterogeneities [59]. The binding
affinity of compound 1 to the protease was determined by
monitoring the chemical shifts of 15N-HSQC cross peaks as a
function of ligand-to-protein concentration ratio. The curves of
different cross peaks were fitted using the following equation which
assumes 1:1 binding stoichiometry
Dd~Ddmax=2 1z L0½ = P0½ zKd= P0½ {ð
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1z L0½ = P0½ zKd= P0½ ð Þ2{4 L0½ = P0½ 
q
where Kd is the dissociation constant, Dd and Ddmax are the
observed and maximal chemical shift change, and [L0] and [P0]
are the total ligand and protein concentrations, respectively.
Fitting was performed using the non-linear fitting option in Origin
6.0 (Microcal, Northampton, MA, USA) [60,61].
Results/Discussion
Validation of the LIECE model on the WNV protease
Experimental IC50 values were first converted into binding free
energy by DG&RT :ln IC50ð Þ, where relative values of IC50 are
assumed to parallel relative free energies of binding in a closely
related series of inhibitors [62,63]. The equations used for fitting
the interaction energy terms to the experimental free energy of
binding are a two-parameter model with continuum electrostatics
[36,37]
DG~aDEvdWzbDGelec ð2Þ
and a three-parameter model with decomposed electrostatics
DG~aDEvdWzb1DECoulzb2DGsolvat ð3Þ
where DEvdW is the intermolecular van der Waals energy and DGelec
Table 1. The two-parameter and three-parameter LIECE models derived using 37 peptide aldehyde inhibitors of WNV protease.
a b or b1 b2 Error
a [kcal/mol] LOOb cv q2
aDEvdWzbDGelec 0.161(7)
c 0.075(11) - 0.93 0.34
aDEvdWzb1DECoulzb2DGsolvat 0.078(21) 0.051(12) 0.045(13) 0.63 0.66
Peptide sequences are listed in Table S-I (found in Text S1).
aRoot mean square of the difference between DG values predicted by LIECE and measured in vitro.
bLeave-one-out cross-validated q2.
cThe standard deviation of the parameters from the leave-one-out procedure is in parentheses, e.g., 0.075(11) abbreviates 0.07560.011.
doi:10.1371/journal.pntd.0000356.t001
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is the sum of two terms: the intermolecular Coulombic energy in vacuo
DECoulð Þ plus the change in solvation energy of inhibitor and protein
upon binding DGsolvatð Þ. Additional models were tested by taking into
account the loss of translational and rotational degrees of freedom
upon binding and the freezing of rotatable bonds of the inhibitor. No
improvement was observed for the 37 peptide aldehyde inhibitors of
WNV protease used in this study.
The parameters obtained by least-squares fitting are given in
Table 1 and the scatter plot of binding energies versus experimental
binding energies is shown in Figure 1. The three-parameter seems to
better fit the experimental data than the two-parameter model as
evidenced by a smaller value in the root mean square of the error in
the energy (0.63 kcal/mol vs. 0.93 kcal/mol), and larger cross-
validated q2 (0.66 vs. 0.34). Therefore, the three-parameter model
was selected as scoring function to prioritize the poses obtained by
high-throughput docking. Note that in this study, 37 peptide
aldehyde inhibitors with either two or three positive charges were
used to derive the LIECE model. Adding neutral inhibitors or
inhibitors with only one formal charge for the fitting leads to worse
results because of the large difference in polarization. For such
inhibitors with broad range of formal charges (from 0 to 3),
semiempirical quantum mechanical calculations can be used to
evaluate polarization effects (an approach termed QMLIECE [64]),
but the present docking campaign and ranking were performed
before the development of QMLIECE.
In Silico Screening
The DAIM decomposition of the 11715 compound library
yielded 1148 unique fragments. These 11715 compounds were
docked by FFLD and the resulting poses of each compound were
first clustered by using a leader algorithm with a similarity cutoff of
0.7 [50,65]. The cluster representatives (a total of 265181 poses)
were further minimized using CHARMM and the CHARMm
force field with a distance-dependent dielectric function. Poses
with less than three hydrogen bonds with the protein were filtered
out. This filter is justified by the strong polar character of the S1–
S3 pockets and the high number of hydrogen bonds observed
Figure 1. Comparison of the calculated versus experimental
binding free energies for 37 peptidic inhibitors of the WNV
protease [13]. Peptide sequences are listed in Table S-I (found in Text
S1). The solid diagonal is the ideal line of perfect prediction. The dashed
diagonals delimit the 1 kcal/mol error region.
doi:10.1371/journal.pntd.0000356.g001
Figure 2. Schematic picture of the in silico screening campaign. Docking of the 11715 compounds with one more positive charges or at least
five hydrogen bond donors was performed by DAIM/SEED/FFLD using the 2fp7 structure of the WNV protease as explained in the text.
doi:10.1371/journal.pntd.0000356.g002
Discovery of NS3 Protease Inhibitor
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between known inhibitors and the WNV protease, e.g., the
aldehyde inhibitor Bz-nKRR-H (IC50 = 4 mM) [13]. The number
of hydrogen bonds formed between compound and protein was
checked for each pose by CHARMM with a cutoff of 3.5 A˚
between donor and acceptor. The 45248 poses forming at least 3
hydrogen bonds with the protein were further selected and
evaluated by LIECE (1902 unique molecules). Finally, the 1000
poses (354 unique compounds) with most favorable LIECE
energies and the 1000 poses (297 unique compounds) with most
intermolecular hydrogen bonds were selected for visual inspection
(Figure 2). A total of 22 compounds were ordered and tested using
NMR spectroscopy (see below). The Kd of compound 1 (Figure 3)
is about 40 mM according to 1H chemical shift (Figure 4). Notably,
compound 1, which has a durene (i.e., 1,2,4,5-tetramethylben-
zene) scaffold linking two positively charged carbamimidothioate
groups, has a ligand efficiency of 0.33 kcal/mol per non-hydrogen
atom, which is good for further development (the threshold being
at about 0.30 kcal/mol per non-hydrogen atom [66]).
Validation by 15N-HSQC NMR spectra
The 22 compounds suggested by high-throughput docking were
tested for binding to the WNV protease by NMR spectroscopy
using 15N-labeled protein. 1D 1H NMR spectra were used to
assess any line broadening experienced by the low-molecular
Figure 3. Compound 1, Kd%40 mM according to
1H chemical
shifts (see Figure 4).
doi:10.1371/journal.pntd.0000356.g003
Figure 4. Binding affinity of compound 1 to WNV NS2B(K96A)-
NS3pro. The changes in 1H chemical shifts of the backbone amide
protons of Thr52 and Glu101 were plotted as a function of increasing
concentration of compound 1. A 10 mM stock solution of compound 1
was titrated into a 80 mM solution of 15N/13C-labeled NS2B(K96A)-
NS3pro containing 20 mM phosphate (pH 7.0) and 2 mM DTT. The 15N-
HSQC spectra were recorded at 25uC on an 800 MHz NMR spectrom-
eter. The Kd value derived from the fitting curves is about 40 mM
(30610 and 50610 mM for the cross-peaks of Thr52 and Glu101,
respectively).
doi:10.1371/journal.pntd.0000356.g004
Figure 5. Superimposition of 15N-HSQC spectra of WNV NS2B(K96A)-NS3pro in the absence (red) and presence (blue) of compound
1 at 25uC. The resonance assignments are shown for selected peaks. The samples contained 0.9 mM protein in 90% H2O/10% D2O, 20 mM HEPES
buffer (pH 7.0), 2 mM DTT. The complex with compound 1 was prepared by titrating the protein solution with a single addition of 15 ml of a DMSO
solution of compound 1 to a final concentration of 3 mM. The spectra were recorded at a 1H NMR frequency of 800 MHz.
doi:10.1371/journal.pntd.0000356.g005
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weight compounds and 15N-HSQC spectra were recorded to
detect responses in the protein. Twelve compounds showed broad
lines in the presence of the WNV protease and six of them showed
specific binding (Text S1). Among them, compound 1 significantly
shifted the 15N-HSQC cross peaks of residues in the substrate
binding site of the protein (Figure 5). The binding affinity of
compound 1 was determined by measuring the change of 1H
chemical shifts of the backbone amide protons of Thr52 and
Glu101, which are located in the active site of the protein, as a
function of increasing concentration of compound 1. Kd values of
30610 mM and 50610 mM were derived from the fits to the
chemical shift changes of Thr52 and Glu101, respectively
(Figure 4). To obtain a structure-activity relation, twelve
commercially available compounds from Sigma-Aldrich and
Maybridge Ltd containing carbamimidoylsulfanylmethyl as a
substructure (Compounds 23–34, see Text S1) were ordered
Figure 6. Binding mode of compound 1. (Top) Interactions between compound 1 and WNV protease. The atoms of the protein and ligand are
shown as balls and colored as carbon in black, oxygen in red, nitrogen in blue, and sulfur in yellow. Intermolecular hydrogen bonds are shown by
green dashed lines with distances in A˚. The intermolecular van der Waals contacts interactions (distance #4 A˚) are shown in red dashed lines. (Figure
made by Ligplot [67]). (Bottom) Stereoview of the binding mode of 1. The protease is shown as cartoon and its secondary structure is emphasized by
different colors: a helices in red, b strands in yellow, and loops in green. Atoms of compound 1 are colored as in the (top) with hydrogens in black.
This figure was prepared using PyMOL (Delano Scientific, San Carlos, CA).
doi:10.1371/journal.pntd.0000356.g006
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and tested by NMR spectroscopy. However, all twelve compounds
showed weaker binding affinities than 1.
Enzymatic assay and tryptophan fluorescence assay
The inhibitory activity of compound 1 was further confirmed by
an enzymatic assay (IC50 = 178 mM, ligand efficiency of 0.28 kcal/
mol per non-hydrogen atom, Text S1) and a tryptophan
fluorescence assay (Kd~83 mM, ligand efficiency of 0.31 kcal/
mol per non-hydrogen atom, Text S1). The binding affinity
measured by three different experimental techniques ranges from
40 mM to 178 mM (and 24.3 kcal/mol as predicted by the LIECE
three-parameter model). These discrepancies might originate from
the intrinsic differences in the mechanism of the three assays. The
15N-HSQC NMR spectra report directly on the binding of the
compound to the protein, and the binding affinity is derived from
the change of 1H chemical shifts of the backbone amide protons of
Thr52 and Glu101. On the other hand, the enzymatic assay and
tryptophan fluorescence assay are both competitive tests. The IC50
is derived in the enzymatic assay by monitoring the competitive
binding of 1 and the (non-natural) substrate (Bz-nKRR-AMC),
while the Kd in the tryptophan fluorescence assay is obtained by
competition with a noncovalent inhibitor (Text S1). Besides these
differences other possible reasons of the discrepancies might be
related to the different conditions of buffers, pH, etc. However, the
specific binding of compound 1 is confirmed by NMR
spectroscopy and its low affinity is probably due to its small size.
Its ligand efficiency calculated using the values from the different
techniques is always close to 0.30 kcal/mol per non-hydrogen
atom, which supports the potential for further development [66].
In fact, the substrate binding site of the WNV protease is large and
there are possibilities to improve the affinity of compound 1 by
medicinal chemistry (see below).
Binding mode and suggestions for further optimization
The binding mode of compound 1 obtained by automatic
docking with FFLD and CHARMM minimization (Figure 6) was
confirmed by NMR spectroscopy [58]. In particular, both methyl
groups and hydrogens of phenyl group (positions 1, 19, 2, and 29,
see Figure 3) are within 5 A˚ from the side chains of His51, Thr132,
Ile155, and Tyr161, which is in agreement with the intermolecular
NOEs. The hydrophobic interactions between two methyl groups
and protein side chains contribute to affinity as confirmed by the
weaker binding (measured by NMR spectroscopy, Text S1) of
compound 23 which is similar to 1 but lacks the two methyl
groups.
In the predicted binding mode, there is a stacking interaction
between the carbamimidothioate moiety and the imidazole ring of
His51 in the S2 pocket. Furthermore, the two positively charged
carbamimidothioate groups are involved in hydrogen bonds with
several residues in the S1 and S2 pockets. The hydrogen bond
acceptor groups in S1 are the Asp129 side chain and Tyr130
backbone carbonyl oxygen, and in S2 they are the Asn152 side
chain as well as the NS2B Asp75 side chain. The lack of activity of
two related compounds (32 and 33, Text S1) with two phenyl
substituents linked to the terminal nitrogens is consistent with the
binding mode of compound 1.
As mentioned above, compound 1 is relatively small (18 heavy
atoms) and occupies only two pockets (S1 and S2) of the substrate
binding site. The binding mode obtained by docking and validated
by NMR spectroscopy suggests that substitutions of one or both
methyl groups of compound 1 might improve its binding affinity.
In particular, replacing a methyl group with a propylamine might
capture additional van der Waals and electrostatic interactions
with residues in the S3 pocket (Figure 7(Left)). The LIECE free
energy of binding of compound 1 and its propylamine derivative
are 24.3 and 24.9 kcal/mol, respectively. Furthermore, replace-
ment of a methyl group with a nitrophenyl-based (Figure 7(Right))
or coumarin-based substituent might yield favorable interactions
with residues at the S19 pocket. These modifications are inspired
by the similar orientations of one of the two methyl groups of
compound 1 and the C-terminal part of the aldehyde inhibitor Bz-
nKRR-H, and the fact that nitrophenyl and coumarin are
expected to bind to the S19 pocket as they are linked at the C-
terminus of the substrate 2-naphthoyl-lysine-lysine-arginine-para-
nitroanilide (2-naphthoyl-KKR-pNA) [4] and Bz-nKRR-AMC
(used in the enzymatic assay of this work), respectively.
Conclusions
High-throughput, fragment-based docking into the active site of
the WNV protease and binding free energy evaluation were used
Figure 7. The protease surface (PDB code 2FP7) is colored according to atomic partial charges. (Left): Binding mode of the propylamine
derivative of compound 1. Compound 1 and its propylamine derivative are in magenta and colored by atom type, respectively. (Right): Binding mode
of the nitrophenyl derivative of compound 1. The substrate 2-naphthoyl-KKR-pNA [4] and the nitrophenyl derivative of compound 1 are in white and
colored by atom type, respectively. The binding mode of the substrate is modelled based on Ref. 4 and only part of it is shown for clarity. These
figures were prepared using PyMOL (Delano Scientific, San Carlos, CA).
doi:10.1371/journal.pntd.0000356.g007
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to select 22 compounds for experimental validation from an initial
library of nearly 12000 molecules. Six of the 22 compounds
showed specific affinity according to the NMR spectra of the
compounds and the protein. Compound 1, which had the most
pronounced effects on the NMR spectrum of the protease, was
further characterized and shown to bind specifically to the active
site with an affinity of about 40 mM (ligand efficiency of 0.33 kcal/
mol per non-hydrogen atom) on the basis of changes of 1H
chemical shifts of the backbone amide protons of two active site
residues. The inhibitory activity of compound 1 was further
validated in an enzymatic assay (IC50 = 183 mM) and a tryptophan
fluorescence assay (Kd~83 mM). Finally, its predicted binding
mode was confirmed by intermolecular NOEs and used to suggest
three chemical modifications with the aim of improving the
binding affinity.
Availability of the Software
The software suite of programs for high-throughput docking
(DAIM, SEED, FFLD), including input files, test cases and
documentation, are available from the corresponding author (at no
expenses for not-for-profit institutions).
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